Calidi Biotherapeutics (NYSE:CLDI) Trading Up 3.4% - Time to Buy?

Calidi Biotherapeutics, Inc. (NYSE:CLDI - Get Free Report)'s stock price rose 3.4% during trading on Friday . The company traded as high as $1.29 and last traded at $1.23. Approximately 227,006 shares traded hands during mid-day trading, an increase of 61% from the average daily volume of 140,845 shares. The stock had previously closed at $1.19.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH initiated coverage on Calidi Biotherapeutics in a report on Thursday, June 27th. They issued a "buy" rating and a $10.00 price objective on the stock.

Calidi Biotherapeutics Price Performance

The business's fifty day moving average is $1.21.

Calidi Biotherapeutics (NYSE:CLDI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.03. On average, equities research analysts expect that Calidi Biotherapeutics, Inc. will post -4.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several hedge funds have recently modified their holdings of the business. Delta Investment Management LLC lifted its position in Calidi Biotherapeutics by 1,955.0% in the second quarter. Delta Investment Management LLC now owns 210,230 shares of the company's stock worth $42,000 after purchasing an additional 200,000 shares during the period. RS Crum Inc. lifted its position in Calidi Biotherapeutics by 2,327.4% in the second quarter. RS Crum Inc. now owns 263,470 shares of the company's stock worth $53,000 after purchasing an additional 252,616 shares during the period. CPR Investments Inc. lifted its position in Calidi Biotherapeutics by 700.0% in the second quarter. CPR Investments Inc. now owns 560,000 shares of the company's stock worth $112,000 after purchasing an additional 490,000 shares during the period. Apollo Management Holdings L.P. bought a new position in Calidi Biotherapeutics in the first quarter worth $71,000. Finally, Magnetar Financial LLC bought a new position in Calidi Biotherapeutics in the first quarter worth $36,000. 12.53% of the stock is owned by institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.